Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis.
Nicolás FissoloPascal BenkertJaume Sastre-GarrigaNeus Mongay-OchoaAndreu Vilaseca-JolonchSara LlufriuYolanda BlancoHarald HegenKlaus BerekFrancisco Perez-MirallesKonrad RejdakLuisa M VillarEnric MonrealRoberto Álvarez-LafuenteOnder K SoyluAhmed AbdelhakFranziska BachhuberHayrettin TumaniSergio Martínez-YélamosAntonio J Sánchez-LópezAntonio García-MerinoLucía GutiérrezTamara Castillo TriviñoJan N LyckeIgal RosensteinRoberto FurlanMassimo FilippiNieves TéllezLluís Ramió-TorrentàJan D LünemannHeinz WiendlSara EichauMicheal KhalilJens KuhleXavier MontalbanManuel Comabella LopezPublished in: Journal of neurology, neurosurgery, and psychiatry (2023)
Levels of sNfL, sGFAP and sCHI3L1 are prognostic biomarkers associated with disability progression in patients with PPMS, being CHI3L1 findings less dependent on the inflammatory component associated with disease progression.